Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286945 | 0.82 | XDH (1.00) | XDHEGFRPI4KAPI4K2BPI4K2A | |
| Hydrochloric Acid SCHEMBL21799342 | 0.81 | XDH (0.97) | XDHEGFRPI4KAPI4K2BPI4K2A | |
| SCHEMBL9705489 | 0.76 | XDH (0.42) | XDHALDH1A1PNPKDM4E | |
| SCHEMBL8302 | 0.76 | XDH (0.39) | XDHALDH1A1MEN1KMT2APNP | |
| SCHEMBL28057316 | 0.73 | XDH (0.39) | XDHALDH1A1MEN1KMT2APNP | |
| SCHEMBL3291325 | 0.73 | CDK1 (0.47) | XDHALDH1A1KMT2AADORA2A | |
| SCHEMBL9001851 | 0.73 | XDH (0.37) | XDHALDH1A1KMT2APNPTSHR | |
| SCHEMBL27886637 | 0.72 | PI4KA (0.64) | XDHEGFRPI4KAPI4K2BPI4K2A | |
| Pyrimidine SCHEMBL28141456 | 0.71 | XDH (0.36) | XDHALDH1A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL16769795 | 0.70 | CDK2 (0.54) | ALDH1A1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680270-B2 | Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| EP-2086546-B1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2086546-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | Viamet Pharmaceuticals, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008064311-A2 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | VIAMET PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305078-A1 | METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES | NQO1, SOD1, MDH2 | XDH 7/4885ALDH1A1 406/4885EGFR 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.